Mark Mlotek Net Worth

The estimated Net Worth of Mark E Mlotek is at least $21.6 Millón dollars as of 14 August 2024. Mr. Mlotek owns over 3,000 units of Henry Schein stock worth over $5,890,410 and over the last 21 years he sold HSIC stock worth over $12,701,103. In addition, he makes $3,009,000 as Chief Strategic Officer, Executive Vice President y Director at Henry Schein.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Mlotek HSIC stock SEC Form 4 insiders trading

Mark has made over 34 trades of the Henry Schein stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of HSIC stock worth $207,360 on 14 August 2024.

The largest trade he's ever made was exercising 36,483 units of Henry Schein stock on 8 March 2012 worth over $1,696,095. On average, Mark trades about 6,732 units every 107 days since 2003. As of 14 August 2024 he still owns at least 87,851 units of Henry Schein stock.

You can see the complete history of Mr. Mlotek stock trades at the bottom of the page.

Mark Mlotek biography

Mark E. Mlotek serves as Chief Strategic Officer, Executive Vice President, Director of the Company. He is also a member of our Executive Management Committee. Mr. Mlotek was Senior Vice President and subsequently Executive Vice President of the Corporate Business Development Group between 2000 and 2012. Prior to that, Mr. Mlotek was Vice President, General Counsel and Secretary from 1994 to 1999. Prior to joining the Company, from 1989 to 1994, Mr. Mlotek was a partner in the law firm of Proskauer Rose LLP, the Company’s principal law firm and one of the largest firms in the nation, specializing in mergers and acquisitions, corporate reorganizations and tax law. As the Company continues to grow through strategic acquisitions, the Board of Directors values Mr. Mlotek’s extensive legal, merger and acquisition and business development experience as well as his drive for innovation and his entrepreneurial spirit. Mr. Mlotek also manages the Company’s important supplier partnership arrangements and global strategic planning function.

What is the salary of Mark Mlotek?

As the Chief Strategic Officer, Executive Vice President y Director of Henry Schein, the total compensation of Mark Mlotek at Henry Schein is $3,009,000. There are 5 executives at Henry Schein getting paid more, with Stanley Bergman having the highest compensation of $14,422,900.

How old is Mark Mlotek?

Mark Mlotek is 64, he's been the Chief Strategic Officer, Executive Vice President y Director of Henry Schein since 2012. There are 14 older and 16 younger executives at Henry Schein. The oldest executive at Henry Schein Inc. is Barry Alperin, 79, who is the Independent Director.

What's Mark Mlotek's mailing address?

Mark's mailing address filed with the SEC is C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE, NY, 11747.

Insiders trading at Henry Schein

Over the last 22 years, insiders at Henry Schein have traded over $272,732,340 worth of Henry Schein stock and bought 23,637 units worth $1,414,559 . The most active insiders traders include Stanley M Bergman, Norman S Matthews y Deborah Derby. On average, Henry Schein executives and independent directors trade stock every 21 days with the average trade being worth of $1,074,342. The most recent stock trade was executed by Lorelei Mc Glynn on 6 September 2024, trading 21,035 units of HSIC stock currently worth $1,457,726.

What does Henry Schein do?

henry schein, inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. the company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. a fortune 500® company and a member of the s&p 500® and nasdaq 100® indexes, henry schein employs more than 18,000 team schein members and serves more than one million customers. the company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. henry schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and henry schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. the company also offers its customers exclusive, innovative technology solutions, including practice

Complete history of Mr. Mlotek stock trades at Henry Schein

Henry Schein executives and stock owners

Henry Schein executives and other stock owners filed with the SEC include:

• Stanley Bergman,
  Chairman of the Board, Chief Executive Officer
• Stanley M. Bergman,
  Exec. Chairman & CEO
• Steven Paladino,
  Chief Financial Officer, Executive Vice President, Director
• Gerald Benjamin,
  Chief Administrative Officer, Executive Vice President, Director
• James Breslawski,
  President, Vice Chairman of the Board, Director
• Mark Mlotek,
  Chief Strategic Officer, Executive Vice President, Director
• James P. Breslawski,
  Exec. Vice Chairman & Pres
• Gerald A. Benjamin,
  Exec. VP, Chief Admin. Officer & Exec. Director
• Steven Paladino,
  Exec. VP, CFO & Exec. Director
• Mark E. Mlotek,
  Exec. VP, Chief Strategic Officer & Exec. Director
• Michael Racioppi,
  Senior Vice President, Chief Merchandising Officer
• Philip Laskawy,
  Lead Independent Director
• Barry Alperin,
  Independent Director
• Joseph Herring,
  Independent Director
• Kurt Kuehn,
  Independent Director
• Bradley Sheares,
  Independent Director
• Carol Raphael,
  Independent Director
• Anne Margulies,
  Independent Director
• Elizabeth Rekow,
  Independent Director
• Shira Goodman,
  Independent Director
• Paul Brons,
  Independent Director
• James Mullins,
  Senior Vice President of Global Services
• Rene Willi,
  President, Global Dental Surgical Group
• David Brous,
  President, Strategic Business Units Group and Asia Pacific & Brazil Dental
• Steven Kess,
  President of the Santa Fe Group
• Carolynne Borders,
  Vice President - Investor Relations
• Jonathan Koch,
  Senior Vice President and Chief Executive Officer, Global Dental Group and Interim Chief Executive Officer, Henry Schein One
• Michael Ettinger,
  Senior Vice President - Corporate and Legal Affairs, Chief of Staff, Secretary
• Lorelei McGlynn,
  Chief Human Resource Officer
• Walter Siegel,
  Senior Vice President, General Counsel
• Christopher Pendergast,
  Senior Vice President, Chief Technology Officer
• Brad Connett,
  President - Henry Schein's U.S. Medical Group
• Olga Timoshkina,
  VP of Corp. Fin., Chief Accounting Officer & Corp. Controller
• Michael Saul Ettinger,
  Exec. VP & COO
• Ronald N. South,
  Sr. VP & CFO
• John Lee,
  VP of Global Compensation & Benefits
• Walter Siegel,
  Chief Legal Officer
• Graham Stanley,
  VP of Investor Relations & Strategic Fin. Project Officer
• Christopher Pendergast,
  Sr. VP & CTO
• Ronald South,
  Chief Accounting Officer & VP of Corp. Fin.
• Paul Rose,
  SVP, Global Supply Chain
• David Mc Kinley,
  President, Medical Group
• Donald J Kabat,
  Director
• Karen Prange,
  EVP&CEO Gl.AH.Med.Den.Sur.Grp
• Lawrence S Bacow,
  Director
• Robert Minowitz,
  President, Int'l Dental Group
• E Dianne Rekow,
  Director
• Peter M. Mc Carthy,
  Pres., Global Animal Health
• Bridget A Ross,
  President, Global Medical Grp
• James A. Harding,
  Chief Technology Officer
• Mohamad Ali,
  
• Deborah Derby,
  
• Michael Zack,
  Senior Vice President
• Larry Gibson,
  Executive V.P. and CTO
• Irving Shafran,
  Director
• Margaret A Hamburg,
  Director
• Marvin Schein,
  
• Pamela Joseph,
  Director
• Stanley Komaroff,
  Senior Advisor
• Lonnie Shoff,
  Pres., Global Healthcare Spec.
• Norman S Matthews,
  Director
• Louis W Sullivan,
  Director
• Karyn Mashima,
  Director
• Leonard A David,
  Vice President
• Reed Vaughn Tuckson,
  
• Scott Philip Serota,
  
• Carole T Faig,
  
• Ronald N. South,
  SVP & Chief Financial Officer